<DOC>
	<DOC>NCT01368055</DOC>
	<brief_summary>The purpose of this trial is to give a shorter course (5 ½-6 weeks) of proton radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of proton radiation, without decreasing the chance of killing prostate cancer cells.</brief_summary>
	<brief_title>Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Prostate cancer. Gleason score 26 or 7. PSA ≤ 20 ng/ml. Previous prostate cancer surgery or pelvic radiation. Prior/concurrent systemic chemotherapy for prostate cancer. Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. History of hip replacement. Prior intrapelvic surgery. Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its uses during radiation. Receiving continuous and current anticoagulation with Warfarin sodium (Coumadin), Clopidogrel bisulfate (Plavix), dabigatran etexilate mesylate (Pradaxa),enoxaparin sodium (Lovenox), or aspirin/er dipyridamole (Aggrenox).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Proton Radiation, Prostate Cancer</keyword>
</DOC>